Chibuzor NG, Prohías MJA, Castro AÁM, Mérida ÁO, Brooks TJ, García HRA

Language: Spanish
References: 22
Page: 229-234
PDF size: 332.57 Kb.

ABSTRACT

Introduction: Cancer is the most dreaded disease known to mankind. Cardiotoxicity is a complication of antineoplastic treatment, which can be detected early by echocardiogram.
Objective: To identify echocardiographic variables related to the occurrence of cardiotoxicity by anthracycline.
Method: A descriptive, prospective and longitudinal study was conducted with all patients admitted to the Hematology Department of Hermanos Ameijeiras Surgical Clinical Hospital, from January 2010 to January 2012. 28 patients who received chemotherapy with anthracyclines were studied. The general information of each patient, as well as the information concerning the transthoracic echocardiogram, was obtained during hospitalization, at one, 6 and 12 months.
Results: 69.3% of patients who developed cardiotoxicity were older than 45 years and there was a predominance of males (76.9%). 56.8% had cardiotoxicity at a dose lower than 550 mg/m2(p = 0.032). Strain rate/Ɛ values in patients who developed cardiotoxicity were significantly reduced at one month [0.8638/0.2 (p = 0.043) and 13.77/ 4.1 (p = 0.031)]; while LVEF remained normal [54.6 ± 4 (p = 0.036)]. Regarding volume/ pressure of the left atrium, there was an increase in the reference values (21.13 ± 5.08 ml and 10.91 ± 0.57 mmHg), although without statistical significance (p = 0.217 and p = 0.728).
Conclusions: Strain rate/Ɛ technique has been helpful for early diagnosis of cardio-toxicity.

REFERENCES

1. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213-20.

2. Takemura G, Fujiwara H. Doxorubicin-induced car-diomyopathy: from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007;49(5):330-52.

3. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. Focused update incorporated into the ACC/AHA guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Car-diology Foundation/American Heart Association

4. Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1-e90.

5. Minotti G, Salvatorrelli E, Menna P. Pharmacolo-gical foundations of cardio-oncology. J Pharmacol Exp Ther. 2010;334(1):2-8.

6. Yeh ET, Bickford CL, Pharm D BC. Cardiovascular complications of cancer therapy: incidence, patho-genesis, diagnosis and management. J Am Coll Cardiol. 2009;53(24):2231-47.

7. Eidem BS. Identification of anthracycline cardiotoxi-city: left ventricular ejection fraction is not enough. J Am Soc Echocardiogr. 2008;21(12):1290-2.

8. Von DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxo-rubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710-7.

9. Gharib MI, Burnett AK. Chemotherapy-induced car-diotoxicity: current practice and prospects of pro-phylaxis. Eur J Heart Fail. 2002;4(3):235-42.

10. Monsuez JJ, Charniot JC, Vighat N, Artigou JY. Car-diac side-effects of cancer chemotherapy. Int J Cardiology. 2010;144(1):3-15.

11. 10.Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. Topoisomerase II beta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Can-cer Res. 2007;67(18):8839-46.

12. 11.Grenier MA, Lipshultz SE. Epidemiology of antracy-cline cardiotoxicity in children and adults. Semin Oncol. 1998;25(4 Suppl 10):72-85.

13. 12.Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525-33.

14. 13.Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a re-trospective analysis of three trials. Cancer. 2003;97: 2869-79.

15. 14.Schimmel KJ, Richel DJ, Van den Brink RB,Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004;30(2):181-91.

16. 15.Mercuro G, Caddeddu C, Piras E, Dessì M, Madeddu C, Deidda M, et al. Early epirubicin myocardial dysfunction revealed by serial Doppler echocardio-graphy. Correlation with inflammatory and oxi-dative stress markers. Oncologist. 2007;1(9):1124-33.

17. 16.Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG,Gietema JA. Cardiovascular toxicity caused by can-cer treatment: strategies for early detection. Lancet Oncol. 2009;10(4):391-9.

18. 17.Marwick TH, Leano RL, Brown J, Sun JP, Hoffmann R, Lysyansky P, et al. Myocardial strain measure-ment with 2-dimensional speckel-tracking echocar-diography: Definition of normal range. JACC Cardio-vasc Imaging. 2009;2(1):80-4.

19. 18.Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction

20. before conventional measures in patients under-going breast cancer treatment with trastuzumab. Am Heart J. 2009;158(2):294-301.

21. 19.Pritchett AM, Jacobsen SJ, Mahoney DW, Rode-heffer RJ, Bailey KR, Redfield MM. Left atrial volume as an index of left atrial size: a population based study. J Am Coll Cardiol. 2003;41(6):1036-43.

22. 20.Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. J Am Coll Cardiol. 2011;107(9):1375-80.